The table below is a review of notable updates that occurred in March 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Researchers have discovered a way to get anti-inflammatory medicine across the blood-brain barrier, opening the door to potential new therapies for a range of conditions, including Alzheimer's disease ...

The U.S. Food and Drug Administration has approved a prefilled syringe version of Netherlands-based Argenx SE's blockbuster ...

A new multimodal tool combines a large language model with powerful graph-based AI models to efficiently find new, synthesizable molecules with desired properties, based on a user's queries in plain ...

Cytochrome P450 (CYP) proteins are responsible for breaking down more than 80% of all Food and Drug Administration ...

Artificial intelligence is increasingly becoming a cornerstone in pharmaceutical research, with numerous companies leveraging ...

Respective industry and government agendas could significantly reshape the US prescription drug market.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the ...

Experimental drug NU-9 - a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) - improves ...

Leading pharmacy benefit managers are shifting away from lucrative rebates on biologic drugs and toward lower-cost biosimilar ...

"The future of drug development lies in precision-driven innovation ... We are particularly excited to launch our first ...